Becky Jubb

HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism

Michael Roche, Martin R. Jakobsen, Jasminka Sterjovski et al. · Journal of Virology · 2011 · 81 citations

Life Sciences, Molecular Biology, Pharmacology +15

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

Michael Roche, Hamid Salimi, Renee C. Duncan et al. · Retrovirology · 2013 · 68 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

Michael Roche, Martin R. Jakobsen, Anne Ellett et al. · Retrovirology · 2011 · 42 citations · Full text

Medicine, Pharmacology, Molecular Pharmacology +15

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets

Jacqueline K. Flynn, Geza Paukovics, Miranda S. Moore et al. · Virology · 2013 · 25 citations

Life Sciences, Immunology, Infectious Diseases +13